Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxorubicin Hydrochloride

FDA-approved product (injectable, injection), marketed as Adriamycin Pfs, Doxil (Liposomal), Doxorubicin Hydrochloride and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Doxorubicin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myelomonocytic leukemia
  • Bone sarcoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • Childhood epithelioid sarcoma
  • Classic Hodgkin lymphoma
  • Epithelioid sarcoma
  • Heart failure
  • HER2 Positive Breast Carcinoma
  • Hodgkins lymphoma
  • Kaposi's sarcoma
  • Malignant epithelial tumor of ovary
  • Multiple myeloma
  • and 9 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
Open Doxorubicin Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxorubicin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

    NCT01313884 · start 2011-05

    Registered record
    Registry ID
    NCT01313884
    Conditions
    Bone Cancer; Ewing's Sarcoma
    Interventions
    Irinotecan; Vincristine; Temozolomide; Doxorubicin; Cytoxan; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2014-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Cancer; Ewing's Sarcoma
    InterventionIrinotecan; Vincristine; Temozolomide; Doxorubicin +2 more
    PhasePhase 2
    Registry statusTerminated

  • A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

    NCT01309789 · start 2011-02

    Registered record
    Registry ID
    NCT01309789
    Conditions
    Lymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventions
    brentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone; cyclophosphamide; doxorubicin; doxorubicin; prednisone; vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-02-28
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventionbrentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone +5 more
    PhasePhase 1
    Registry statusCompleted

  • International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

    NCT01117441 · start 2010-06

    Registered record
    Registry ID
    NCT01117441
    Conditions
    Leukemia
    Interventions
    PEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; vindesine; daunoxome; fludarabine; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2021-12-31
    Enrolment
    6,136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionPEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride +13 more
    PhasePhase 3
    Registry statusCompleted

  • Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

    NCT01004380 · start 2009-11

    Registered record
    Registry ID
    NCT01004380
    Conditions
    Epithelial Ovarian Cancer
    Interventions
    Farletuzumab, Carboplatin, and PLD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2012-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpithelial Ovarian Cancer
    InterventionFarletuzumab, Carboplatin, and PLD
    PhasePhase 1
    Registry statusCompleted

  • Doxil, Bevacizumab and Temsirolimus Trial

    NCT00761644 · start 2008-08-21

    Registered record
    Registry ID
    NCT00761644
    Conditions
    Advanced Cancer
    Interventions
    Doxil; Bevacizumab; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08-21
    Completion
    2019-03-28
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionDoxil; Bevacizumab; Temsirolimus
    PhasePhase 1
    Registry statusCompleted

  • Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

    NCT00656669 · start 2008-04

    Registered record
    Registry ID
    NCT00656669
    Conditions
    Breast Cancer
    Interventions
    sunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-04
    Completion
    2010-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionsunitinib alone; sunitinib plus paclitaxel; doxorubicin and cyclophosphamide
    PhaseNot applicable
    Registry statusCompleted

  • Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

    NCT00470067 · start 2007-02

    Registered record
    Registry ID
    NCT00470067
    Conditions
    Endometrial Cancer
    Interventions
    carboplatin; pegylated liposomal doxorubicin hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-02
    Completion
    2009-12
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    Interventioncarboplatin; pegylated liposomal doxorubicin hydrochloride
    PhasePhase 2
    Registry statusTerminated

  • Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

    NCT00408408 · start 2006-11

    Registered record
    Registry ID
    NCT00408408
    Conditions
    Breast Cancer
    Interventions
    bevacizumab; capecitabine; cyclophosphamide; docetaxel; doxorubicin hydrochloride (Adriamycin); gemcitabine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-11
    Completion
    2018-03
    Enrolment
    1,206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab; capecitabine; cyclophosphamide; docetaxel +2 more
    PhasePhase 3
    Registry statusUnknown

  • Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

    NCT00426127 · start 2006-11

    Registered record
    Registry ID
    NCT00426127
    Conditions
    Pancreatic Cancer
    Interventions
    Docetaxel; Liposomal Doxorubicin; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-11
    Completion
    2009-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionDocetaxel; Liposomal Doxorubicin; Enoxaparin
    PhasePhase 2
    Registry statusTerminated

  • Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

    NCT00107198 · start 2006-03-10

    Registered record
    Registry ID
    NCT00107198
    Conditions
    Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    Interventions
    Conventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone; Radiation Therapy; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03-10
    Completion
    2026-03-31
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnn Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    InterventionConventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone +2 more
    PhasePhase 2
    Registry statusCompleted

  • Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma

    NCT02240771 · start 2006-01

    Registered record
    Registry ID
    NCT02240771
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Transarterial chemotherapy; Oral chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2006-01
    Completion
    2015-03
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionTransarterial chemotherapy; Oral chemotherapy
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

    NCT00270894 · start 2005-11

    Registered record
    Registry ID
    NCT00270894
    Conditions
    Breast Neoplasm
    Interventions
    epirubicin; cyclophosphamide; docetaxel; trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2011-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm
    Interventionepirubicin; cyclophosphamide; docetaxel; trastuzumab
    PhasePhase 2
    Registry statusCompleted

  • To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

    NCT00082095 · start 2004-04

    Registered record
    Registry ID
    NCT00082095
    Conditions
    Metastatic Breast Cancer
    Interventions
    Pegylated liposomal doxorubicin; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-04
    Completion
    2005-12
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPegylated liposomal doxorubicin; Capecitabine
    PhasePhase 3
    Registry statusTerminated

  • Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

    NCT00194779 · start 2003-10

    Registered record
    Registry ID
    NCT00194779
    Conditions
    Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer
    Interventions
    doxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim; capecitabine; methotrexate; vinorelbine tartrate; needle biopsy; therapeutic conventional surgery; immunohistochemistry staining method; trastuzumab; tamoxifen citrate; letrozole; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10
    Completion
    2011-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer +5 more
    Interventiondoxorubicin hydrochloride; cyclophosphamide; paclitaxel; filgrastim +10 more
    PhasePhase 2
    Registry statusCompleted

  • Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    NCT00062296 · start 2003-03

    Registered record
    Registry ID
    NCT00062296
    Conditions
    Leukemia; Lymphoma
    Interventions
    rituximab; epirubicin hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-03
    Completion
    2005-08
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventionrituximab; epirubicin hydrochloride
    PhasePhase 2
    Registry statusCompleted